Loading...
AGY logo

Allergy Therapeutics plcAIM:AGY Stock Report

Market Cap UK£340.7m
Share Price
n/a
1Y-29.8%
7D7.3%
1D9.7%
Portfolio Value
​
View

Allergy Therapeutics plc

AIM:AGY Stock Report

Market Cap: UK£340.7m

Allergy Therapeutics (AGY) Stock Overview

A commercial biotechnology company, focuses on the diagnosis and treatment of allergic disorders in Germany, Austria, United Kingdom, Netherlands, Switzerland, Italy, Spain, and internationally. More details

AGY fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health2/6
Dividends0/6

Risk Analysis

Shareholders have been substantially diluted in the past year

Earnings have declined by 38.9% per year over past 5 years

Has less than 1 year of cash runway

Volatile share price over the past 3 months compared to the UK market


AGY Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

NEW492,148 members

Join community and earn perks

Gain real feedbackFrom our editorial team, personally. Not silence.
Grow your followingReal investors. The kind who actually invest, not scroll past.
Unlock free accessFree premium subscription for consistent and quality authors.
Learn moreCreate Narrative
BL
BlackGoat
IN
Investingwilly
RO
RockeTeller
DA
davidlsander
492,148 investors already sharing narratives
View all narratives

Allergy Therapeutics plc Competitors

Price History & Performance

Summary of share price highs, lows and changes for Allergy Therapeutics
Historical stock prices
Current Share PriceUK£0.059
52 Week HighUK£0.12
52 Week LowUK£0.05
Beta0.87
1 Month Change-15.71%
3 Month Change-46.12%
1 Year Change-29.76%
3 Year Change78.79%
5 Year Change-80.00%
Change since IPO-92.08%

Recent News & Updates

Recent updates

Analysis Article • Dec 16

Market Participants Recognise Allergy Therapeutics plc's (LON:AGY) Revenues Pushing Shares 30% Higher

Allergy Therapeutics plc ( LON:AGY ) shareholders have had their patience rewarded with a 30% share price jump in the...
Analysis Article • Aug 30

The Price Is Right For Allergy Therapeutics plc (LON:AGY)

When you see that almost half of the companies in the Pharmaceuticals industry in the United Kingdom have...
Analysis Article • May 09

Investors Appear Satisfied With Allergy Therapeutics plc's (LON:AGY) Prospects As Shares Rocket 26%

Allergy Therapeutics plc ( LON:AGY ) shareholders would be excited to see that the share price has had a great month...
Analysis Article • Nov 09

Allergy Therapeutics plc (LON:AGY) Soars 27% But It's A Story Of Risk Vs Reward

Allergy Therapeutics plc ( LON:AGY ) shares have had a really impressive month, gaining 27% after a shaky period...
Analysis Article • Sep 12

Not Many Are Piling Into Allergy Therapeutics plc (LON:AGY) Just Yet

With a median price-to-sales (or "P/S") ratio of close to 3.8x in the Pharmaceuticals industry in the United Kingdom...
Analysis Article • May 21

Allergy Therapeutics plc's (LON:AGY) 28% Share Price Surge Not Quite Adding Up

Allergy Therapeutics plc ( LON:AGY ) shareholders have had their patience rewarded with a 28% share price jump in the...
Analysis Article • Dec 18

Allergy Therapeutics plc (LON:AGY) Surges 28% Yet Its Low P/S Is No Reason For Excitement

Allergy Therapeutics plc ( LON:AGY ) shareholders are no doubt pleased to see that the share price has bounced 28% in...

Shareholder Returns

AGYGB PharmaceuticalsGB Market
7D7.3%4.4%2.4%
1Y-29.8%19.4%18.4%

Return vs Industry: AGY underperformed the UK Pharmaceuticals industry which returned 19.4% over the past year.

Return vs Market: AGY underperformed the UK Market which returned 18.4% over the past year.

Price Volatility

Is AGY's price volatile compared to industry and market?
AGY volatility
AGY Average Weekly Movement10.4%
Pharmaceuticals Industry Average Movement4.6%
Market Average Movement5.1%
10% most volatile stocks in GB Market10.6%
10% least volatile stocks in GB Market2.7%

Stable Share Price: AGY's share price has been volatile over the past 3 months compared to the UK market.

Volatility Over Time: AGY's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of UK stocks.

About the Company

FoundedEmployeesCEOWebsite
1998584Manuel Llobetwww.allergytherapeutics.com

Allergy Therapeutics plc, a commercial biotechnology company, focuses on the diagnosis and treatment of allergic disorders in Germany, Austria, United Kingdom, Netherlands, Switzerland, Italy, Spain, and internationally. The company sells injectable and sublingual allergen-specific immunotherapies, and offers treatment of pollen-related allergies, particularly to grasses, weeds, and trees, as well as diagnostics products. Its products include Pollinex Quattro, Oralvac, Venomil, Venom ATL Polistes Dominula, Synbiotics, and Acarovac Plus.

Allergy Therapeutics plc Fundamentals Summary

How do Allergy Therapeutics's earnings and revenue compare to its market cap?
AGY fundamental statistics
Market capUK£340.69m
Earnings (TTM)-UK£48.17m
Revenue (TTM)UK£57.29m
6.5x
P/S Ratio
-7.8x
P/E Ratio

Is AGY overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
AGY income statement (TTM)
RevenueUK£57.29m
Cost of RevenueUK£27.38m
Gross ProfitUK£29.92m
Other ExpensesUK£78.09m
Earnings-UK£48.17m

Last Reported Earnings

Dec 31, 2025

Next Earnings Date

n/a

Earnings per share (EPS)-0.0076
Gross Margin52.22%
Net Profit Margin-84.08%
Debt/Equity Ratio474.5%

How did AGY perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/07/29 17:47
End of Day Share Price 2026/07/29 00:00
Earnings2025/12/31
Annual Earnings2025/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Allergy Therapeutics plc is covered by 5 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Adam McCarterCavendish
Paul CuddonPeel Hunt LLP
Mohammad FazeliPiper Sandler Companies